Nonetheless, the panel argues that patients with “SMARCB1-deficient non-RT neoplasms” should be offered genetic testing on a research basis and, if positive for a PV, cancer surveillance ideally in the setting of a tumor predisposition clinic. The gene discussed is SMARCB1; the disease is cancer.